Proactive - Interviews for investors
Tonix Pharmaceuticals announces key topline data from 2nd Phase 3 Clinical Trial of TNX-102 SL
This episode appears to contain dynamically inserted ads. Transcript timestamps may be approximate.
Proactive - Interviews for investors